E-commerce giant Amazon.com (AMZN) completed its much talked about 20-for-1 stock split on June 06, 2022, which led its shares to trade below $1000 for the first time since 2017….
Author archives: Pragya Pandey
Is WPP a Good Stock to Add to Your Dividend Portfolio?
Despite WPP plc’s (WPP) significant efforts to boost its operational performance, its shares are down 35.1% year-to-date. So, let’s evaluate if it is worth adding the stock to your dividend…
With Oil Prices Surging, Is Nordic American Tankers a Buy?
Nordic American Tankers (NAT) anticipates increased demand for their Suezmax tankers in the coming days since OPEC and Saudi Arabia decided to expand oil output by more than the previously…
Is Globant S.A. a Software Stock Worth Buying?
Globant S.A. (GLOB) posted solid financial results in the last reported quarter and also beat the consensus revenue and earnings estimates. However, the stock has plunged nearly 43% year-to-date. So,…
Here’s Why Vodafone Should Be on Your Watchlist
Telecom operator Vodafone Group (VOD) recently highlighted concerns about rising inflation and increasing economic instabilities that could impede its growth. However, given the surging demand for telecom services and increasing…
Is Paylocity a Good Cloud Stock to Add to Your Portfolio?
Despite several strategic advancements, Paylocity’s (PCTY) shares are down 26.6% year-to-date. Also, the stock is currently trading at a significant premium to its peers, so would it be worth buying…
Is Fastly Stock a Buy or a Sell?
Content delivery network and software company Fastly (FSLY) reported revenue growth of nearly 20.7% in its last quarterly release. However, the stock has slumped nearly 64% in price year-to-date. So,…
Digital Turbine: Down More Than 65% YTD, is Now a Good Time to Scoop Up Shares?
The shares of Digital Turbine (APPS) have plunged nearly 66% in price year-to-date on investors’ pessimism surrounding its prospects. So, let’s evaluate if it is worth adding the stock to…
Is OPKO Health a Diagnostics Stock Worth Buying?
Multinational biopharmaceutical company OPKO Health’s (OPK) stock climbed nearly 13% in price last year when the company announced its plans to acquire ModeX Therapeutics. However, given the company’s declining financials…
Altice USA: Down 30% YTD, is Now a Good Time to Buy?
Altice USA’s (ATUS) shares are down more than 30% in price year-to-date based on its poor fundamental performance. So, let’s evaluate if it is worth adding the stock to one’s…